(Adnkronos) - “I progetti premiati, nel settore dell’oncologia, sono molto innovativi e mirano a caratterizzare dal punto di vista biologico i tumori umani per predire con la maggior precisione possibile la loro evoluzione e la loro responsività alle terapie disponibili”. Lo ha detto Pierfranco Conte, professore di Oncologia dell’università di Padova, in occasione dell’evento di premiazione dei progetti vincitori della 13esima edizione dei Bandi di Gilead Sciences, dedicati alla ricerca nell’area delle malattie infettive, delle patologie oncologiche ed ematologiche.
Category
🗞
NewsTranscript
00:00I've been part of the committee that chooses the projects to be awarded for a few years now and I'm becoming more and more aware of the importance of this program.
00:13We are all convinced of the importance of research and innovation, but we are less aware of how difficult it is for a young person to start a research path.
00:23Unfortunately, it is much easier for a senior person to obtain funding for research and much more difficult for a young person.
00:31Young people, on the other hand, often have much more innovative ideas, much more groundbreaking ideas than senior people.
00:37The good thing about this program is that it allows many young people to start a scientific career that often results in high-level results.
00:49As far as the oncology sector is concerned, there are two main characteristics.
00:54On the one hand, very innovative projects that aim to characterize human tumors from a biological point of view and to predict their evolution and responsiveness to the available therapies.
01:10On the other hand, projects that aim to improve the quality of life of oncological patients.
01:17So, not only to cure these patients, but to move from healing to the well-being of these patients.